NASDAQ
6.96USD
-0.53 (-7.08%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
289.8M
P/E
—
EPS
—
Beta
1.55
52W range
2.71-8.7
Day range
6.92–7.55
Open
7.52
Prev close
7.49
Volume
1.2M
Avg volume
3.8M
Dividend
0.00
IPO
2000-02-08
https://www.zacks.com/stock/news/2971465/agenus-agen-reports-q2-loss-tops-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|yseop_template_4-2971465 · 8/7/2026-0.40
https://www.zacks.com/stock/news/2933408/agen-bot-bal-what-the-battman-trial-means-for-mcrc?cid=CS-STOCKNEWSAPI-FT-analyst_blog_plus|zer_report_insights-2933408 · 6/5/2026+0.40
https://www.zacks.com/stock/news/2928355/agen-vs-iova-which-cancer-biotech-stock-has-more-upside-potential?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2928355 · 5/28/2026+0.40
https://www.businesswire.com/news/home/20260521604737/en/Agenus-and-Noetik-Present-ASCO-2026-Data-Linking-AI-Analysis-of-Routine-Pretreatment-Tumor-Pathology-Images-to-Response-and-Survival-with-BOTBAL-in-MSS-Metastatic-CRC/ · 5/21/2026+0.60
https://www.businesswire.com/news/home/20260417821181/en/Agenus-Reports-Phase-II-Data-Demonstrating-Immune-Reprogramming-and-Durable-Survival-with-Botensilimab-Balstilimab-and-agenT-797-in-PD-1-Refractory-Gastroesophageal-Cancer/ · 4/17/2026+0.50
https://www.zacks.com/stock/news/2894363/can-agenus-agen-run-higher-on-rising-earnings-estimates · 4/3/2026+1.00
https://www.zacks.com/stock/news/2894250/has-agenus-agen-outpaced-other-medical-stocks-this-year · 4/3/2026+1.00
https://www.businesswire.com/news/home/20260317452517/en/Agenus-Announces-Upcoming-AACR-2026-Presentation-Evaluating-Botensilimab-Plus-Balstilimab-in-First-Line-MSS-Metastatic-Colorectal-Cancer/ · 3/17/2026+0.50
https://www.zacks.com/stock/news/2884876/agenus-agen-q4-earnings-and-revenues-surpass-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2884876 · 3/17/2026+0.60
https://www.businesswire.com/news/home/20260304473547/en/Agenus-to-Provide-Fourth-Quarter-and-Year-end-2025-Financial-Report-and-Corporate-Update/ · 3/4/2026+0.00
https://www.businesswire.com/news/home/20260120995688/en/Agenus-to-Host-First-2026-Stakeholder-Webcast/ · 1/20/2026+0.30
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
